Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing CAR-T cell therapies for AL amyloidosis and other serious diseases. Its lead program, NXC-201, is in Phase 1b/2 clinical testing in the U.S. and ex-U.S., with orphan drug designations from both the FDA and European Commission.

10.01

10.01

— Immix Biopharma, Inc.
%
Lead cell therapy program0% Development of NXC-201, a CAR-T therapy targeting AL amyloidosis and other serious diseases.
Clinical trial operations0% Execution of U.S. and ex-U.S. clinical studies to generate safety and efficacy data.
Manufacturing and scale-up0% Manufacturing of product candidates for trials, regulatory readiness, and eventual commercialization.
Intellectual property and development platform0% Patent prosecution, licensing, and development of additional product candidates or technologies.

Immix Biopharma does not sell commercial products yet; its immediate counterparties are clinical trial sites,...

  • Clinical trial participantsprimary

    Patients with AL amyloidosis enrolled in NEXICART-1 and NEXICART-2 to evaluate safety and efficacy.

  • Clinical investigators and trial sitesprimary

    Hospitals and research centers that administer the studies and generate regulatory-grade data.

  • Future specialty treatment centerssecondary

    Hospitals and infusion centers that could use NXC-201 if it receives regulatory approval.

  • Grant and capital providersprimary

    Public and private funding sources that finance R&D, manufacturing, and regulatory work.

Immix Biopharma is headquartered in the United States and runs its lead clinical program in both the U.S. and ex-U.S...

  • •United States is the core operating base and primary clinical market
  • •NEXICART-2 is a U.S. Phase 1b/2 study
  • •NEXICART-1 is an ex-U.S. Phase 1b/2a study
  • •Australian subsidiary creates some non-U.S. tax exposure
  • •No commercial revenue geography disclosed; business remains development-stage

The company’s strategy is to advance NXC-201 through clinical development, secure regulatory support, and build the...

01
Clinical advancement of NXC-201short-term

Clinical data is the main value driver for a pre-revenue cell therapy company.

02
Regulatory and orphan-drug positioningmedium-term

Regulatory designations can improve development efficiency and market access prospects.

03
Manufacturing and commercialization readinessmedium-term

Cell therapies require specialized supply chain and manufacturing scale before launch.

Immix Biopharma is exposed to the typical risks of a clinical-stage biotech: trial failure, regulatory delay, and the...

critical

Ability to continue as a going concern

The company has recurring losses, negative operating cash flow, and depends on external capital and grants.

Scope
Pre-revenue development-stage operations
Materiality
high
high

Clinical development failure

NXC-201 is still in early-stage trials, so safety or efficacy issues could halt development.

Scope
NEXICART-1 and NEXICART-2
Materiality
high
high

Regulatory approval risk

Approval depends on trial outcomes and regulator review, which can be delayed or denied.

Scope
FDA and EMA pathways
Materiality
high
high

Capital raising and dilution

The business is funded primarily through equity offerings and grant reimbursements.

Scope
Future financings
Materiality
high
medium

Manufacturing and scale-up execution

Cell therapy production is complex and costly, especially before commercial launch.

Scope
Clinical supply and future commercial readiness
Materiality
medium
Research and development expense timing
Affects operating loss and comparability across periods
Grant accounting
Affects other income and net cash burn
Intangible asset and long-lived asset valuation
Potential impairment charges if program value weakens
Revenue recognition
Could materially change reported results once commercialization begins

Nkarta, Inc.

NKTX · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Nurix Therapeutics, Inc.

NRIX · Pharmaceutical Preparations

Annexon, Inc.

ANNX · Pharmaceutical Preparations

: 28/04/2026